What Would You Do to Protect $50 Billion a Year?

By Amanda Frost, PhD Vice President, Research, PCMA Did you know: the original patent for semaglutide – better known as Ozempic – should have expired this year. Today, incredible hope for human health rests in drugs like semaglutide. But they highlight the tension between breakthroughs in medicine and access to these promising therapies. They also […]

PCMA: FEHB Bill is a Taxpayer Giveaway to Pharmacists

(WASHINGTON, D.C.) – Today, the House Committee on Oversight and Government Reform is considering H.R. 6610, the Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]. The legislation mandates minimum reimbursement rates for pharmacies participating in the Federal Employee Health Benefit plan (FEHB), adding significant cost to the program with no added benefit to enrollees. David Marin, President and CEO, […]

PCMA Statement on PBM-Related Bills Considered by Senate HELP Committee

(WASHINGTON, D.C.) – Pharmaceutical Care Management Association (PCMA) President and CEO, David Marin, issued the following statement on today’s markup in the Senate Committee on Health, Education, Labor, and Pensions (HELP), which includes consideration of S. 2355, Patients Deserve Price Tags Act and S. 4189, the INSULIN Act of 2026. “Congress achieved a major victory this year by enshrining unprecedented PBM transparency into federal law. The priority now […]